1369489-71-3
1369489-71-3
Chemical Structure
Palupiprant
Synonym(s): E7046
- CAS No.: 1369489-71-3
- Formula:C22H18F5N3O4
- Molecular Weight:483.39
IUPAC Name: (S)-4-(1-(3-(difluoromethyl)-1-methyl-5-(3-(trifluoromethyl)phenoxy)-1H-pyrazole-4-carboxamido)ethyl)benzoic acid
InChIKey: MKLKAQMPKHNQPR-NSHDSACASA-N
SMILES: O=C(O)C1=CC=C([C@@H](NC(C2=C(OC3=CC=CC(C(F)(F)F)=C3)N(C)N=C2C(F)F)=O)C)C=C1
Biological Activity: Palupiprant (E7046) is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM. Palupiprant exhibits anti-tumor activities[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Palupiprant | 99.96% | Palupiprant (E7046) is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM. Palupiprant exhibits anti-tumor activities. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Palupiprant (Standard) | ≥98% | Palupiprant (Standard) is the analytical standard of Palupiprant (HY-103088). This product is intended for research and analytical applications. Palupiprant (E7046) is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM. Palupiprant exhibits anti-tumor activities. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.57
HY-122168AAT-008 -
Similarity Score 0.56
HY-133123EP4 receptor antagonist 1 -
Similarity Score 0.52
HY-182278Flubeneteram -
Similarity Score 0.52
HY-10797CJ-42794 -
Similarity Score 0.51
HY-139851Fungicide5 -
Similarity Score 0.49
HY-158981Herbicide safener-3 -
Similarity Score 0.48
HY-141448NRX-2663 -
Similarity Score 0.47
HY-10413MK-2894 -
Similarity Score 0.47
HY-169859EP4 receptor antagonist 7 -
Explore the MedChemAI to find more analogs
References
- [1]. X. Bao, et al. Combination of a Novel EP4 Antagonist E7046 and Radiation Therapy Promotes Anti-tumor Immune Response and Tumor Rejection in Preclinical Tumor Models. International Journal of Radiation Oncology Biology Physics
- [2]. Diana I. Albu, et al. EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity. Oncoimmunology. 2017 Jun 28;6(8):e1338239. [Content Brief]
